BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGuirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, Keir C, Myers GD. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy 2017;19:1015-24. [PMID: 28754600 DOI: 10.1016/j.jcyt.2017.06.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Ilieva KM, Cheung A, Mele S, Chiaruttini G, Crescioli S, Griffin M, Nakamura M, Spicer JF, Tsoka S, Lacy KE, Tutt ANJ, Karagiannis SN. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. Front Immunol 2017;8:1911. [PMID: 29375561 DOI: 10.3389/fimmu.2017.01911] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
2 Chen LN, Collins-Johnson N, Sapp N, Pickett A, West K, Stroncek DF, Panch SR. How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing? Transfusion 2019;59:2506-18. [PMID: 31135995 DOI: 10.1111/trf.15349] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
3 Calmels B, Mfarrej B, Chabannon C. From clinical proof-of-concept to commercialization of CAR T cells. Drug Discov Today 2018;23:758-62. [PMID: 29317339 DOI: 10.1016/j.drudis.2018.01.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
4 Strati P, Neelapu SS. Chimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma. Curr Oncol Rep 2019;21. [DOI: 10.1007/s11912-019-0789-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sánchez-Escamilla M, Yáñez San Segundo L, Urbano-Ispizua Á, Perales MÁ. CAR T cells: The future is already present. Med Clin (Barc) 2019;152:281-6. [PMID: 30392694 DOI: 10.1016/j.medcli.2018.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hanley PJ, Bersenev A, Gustafson MP. Delivering externally manufactured cell and gene therapy products to patients: perspectives from the academic center experience. Cytotherapy 2021:S1465-3249(21)00820-3. [PMID: 34753676 DOI: 10.1016/j.jcyt.2021.09.010] [Reference Citation Analysis]
7 Wall DA, Krueger J. Chimeric antigen receptor T cell therapy comes to clinical practice. Curr Oncol 2020;27:S115-23. [PMID: 32368181 DOI: 10.3747/co.27.5283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
8 Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 2022. [PMID: 35318469 DOI: 10.1038/s41571-022-00607-3] [Reference Citation Analysis]
9 Marzal-Alfaro MB, Escudero-Vilaplana V, Revuelta-Herrero JL, Collado-Borrell R, Herranz-Alonso A, Sanjurjo-Saez M. Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective. Front Oncol 2021;11:636068. [PMID: 33777790 DOI: 10.3389/fonc.2021.636068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Thomas X, Paubelle E. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia. Expert Opinion on Biological Therapy 2018;18:1095-106. [DOI: 10.1080/14712598.2018.1533951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Pang Y, Hou X, Yang C, Liu Y, Jiang G. Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Mol Cancer 2018;17:91. [PMID: 29769134 DOI: 10.1186/s12943-018-0840-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
12 Verneris MR, Ma Q, Zhang J, Keating A, Tiwari R, Li J, Yang H, Agarwal A, Pacaud L. Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. Blood Adv 2021;5:5387-95. [PMID: 34597381 DOI: 10.1182/bloodadvances.2020004045] [Reference Citation Analysis]
13 Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 2020;4:1440-7. [PMID: 32271898 DOI: 10.1182/bloodadvances.2019001305] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
14 Pacenta HL, Laetsch TW, John S. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. Paediatr Drugs 2020;22:1-11. [PMID: 31749131 DOI: 10.1007/s40272-019-00370-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, Mgebroff S, Linn N, Delaney M, Gardner RA. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion 2018;58:1414-20. [PMID: 29536556 DOI: 10.1111/trf.14569] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
16 Thibodeaux SR, Aqui NA, Park YA, Schneiderman J, Su LL, Winters JL, Zubair AC, Schwartz J, Liu HD; Immune Effector Cell Therapy Subcommittee, Clinical Applications Committee, American Society for Apheresis. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies. J Clin Apher 2022. [PMID: 35085413 DOI: 10.1002/jca.21964] [Reference Citation Analysis]
17 Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe. Hemasphere 2018;2:e18. [PMID: 31723747 DOI: 10.1097/HS9.0000000000000018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
18 Strati P, Patel S, Nastoupil L, Fanale MA, Bollard CM, Lin AY, Gordon LI. Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200549] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Raikar SS, Spencer HT. Hurdles Associated with the Translational Use of Genetically Modified Cells. Curr Stem Cell Rep 2018;4:39-45. [PMID: 33381387 DOI: 10.1007/s40778-018-0115-y] [Reference Citation Analysis]
20 Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 2019;16:45-63. [PMID: 30082906 DOI: 10.1038/s41571-018-0075-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 30.0] [Reference Citation Analysis]
21 Petrich J, Marchese D, Jenkins C, Storey M, Blind J. Gene Replacement Therapy: A Primer for the Health-system Pharmacist. J Pharm Pract 2020;33:846-55. [PMID: 31248331 DOI: 10.1177/0897190019854962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
22 Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA; CAR T-cell Consortium. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant 2020;26:1239-46. [PMID: 32298807 DOI: 10.1016/j.bbmt.2020.04.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
23 Fujiwara Y, Kato T, Hasegawa F, Sunahara M, Tsurumaki Y. The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy. Pharmaceuticals 2022;15:207. [DOI: 10.3390/ph15020207] [Reference Citation Analysis]
24 Tyagarajan S, Schmitt D, Acker C, Rutjens E. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor–T cell manufacture. Cytotherapy 2019;21:1198-205. [DOI: 10.1016/j.jcyt.2019.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Britten CM, Shalabi A, Hoos A. Industrializing engineered autologous T cells as medicines for solid tumours. Nat Rev Drug Discov 2021;20:476-88. [PMID: 33833444 DOI: 10.1038/s41573-021-00175-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yan W, Hu H, Tang B. Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer. Onco Targets Ther 2019;12:8015-22. [PMID: 31686857 DOI: 10.2147/OTT.S203550] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
27 Bouziana S, Bouzianas D. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not? Biology of Blood and Marrow Transplantation 2020;26:e183-91. [DOI: 10.1016/j.bbmt.2020.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
28 Iancu EM, Kandalaft LE. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting. Current Opinion in Biotechnology 2020;65:233-41. [DOI: 10.1016/j.copbio.2020.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Laetsch TW, Yanik GA, Boyer MW, Rheingold SR. An owner's manual for CD19 "CAR"-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. Blood Rev 2021;:100848. [PMID: 33994222 DOI: 10.1016/j.blre.2021.100848] [Reference Citation Analysis]
30 Gowda L, Shah NC. CAR-T cell manufacture: snatching victory when defeat is looming. Transfusion 2018;58:1335-7. [PMID: 29949188 DOI: 10.1111/trf.14760] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. JAMA Netw Open 2020;3:e202072. [PMID: 32250433 DOI: 10.1001/jamanetworkopen.2020.2072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
32 Munshi PN, Ujjani C. The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma. Hematological Oncology 2019;37:233-9. [DOI: 10.1002/hon.2568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Booth JP, Kusoski CL, Kennerly-Shah JM. The pharmacist's role in chimeric antigen receptor T cell therapy. J Oncol Pharm Pract 2020;26:1725-31. [PMID: 32819199 DOI: 10.1177/1078155220948940] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Cahill KE, Leukam MJ, Riedell PA. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leukemia & Lymphoma 2020;61:799-807. [DOI: 10.1080/10428194.2019.1691201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L, Coscia M, Maloy M, Sanchez-Escamilla M, Elsabah H, Fadul A, Maffini E, Pittari G, Bruno B. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Front Immunol 2020;11:888. [PMID: 32477359 DOI: 10.3389/fimmu.2020.00888] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
36 Lam C, Meinert E, Halioua-Haubold CL, Carter A, Yang A, Brindley D, Cui Z. Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery. BMJ Open 2019;9:e026172. [PMID: 31278092 DOI: 10.1136/bmjopen-2018-026172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Seber A, de CastroJunior CG, Kerbauy LN, Hirayama AV, Bonfim C, Fernandes JF, Souza M, Schafell R, Nabhan S, Loggetto SR, Simões BP, Rocha V, de Lima M, Guerino-Cunha RL, Bittencourt H. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. Hematol Transfus Cell Ther 2021;43 Suppl 2:S13-21. [PMID: 34794791 DOI: 10.1016/j.htct.2021.09.002] [Reference Citation Analysis]
38 Elverum K, Whitman M. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Gene Ther 2020;27:537-44. [PMID: 31024072 DOI: 10.1038/s41434-019-0074-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
39 Paroder M, Le N, Pham HP, Thibodeaux SR. Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells. Adv Cell Gene Ther 2020;3. [DOI: 10.1002/acg2.75] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Forsberg MH, Das A, Saha K, Capitini CM. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Ther Clin Risk Manag 2018;14:1573-84. [PMID: 30233192 DOI: 10.2147/TCRM.S146309] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
41 Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Des Devel Ther 2018;12:3885-98. [PMID: 30518999 DOI: 10.2147/DDDT.S138765] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
42 Aftab BT, Sasu B, Krishnamurthy J, Gschweng E, Alcazer V, Depil S. Toward “off‐the‐shelf” allogeneic CAR T cells. Adv Cell Gene Ther 2020;3. [DOI: 10.1002/acg2.86] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]